Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Goldberg

Showing results (21-30 of 105) with videos related to

Pageof 11
Sort By:
Radiology|September 19, 2018
Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database StudyJohannes Uhlig, Johannes M Ludwig, Sarah B Goldberg, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2024
Navigating the Complexities of Brain Metastases ManagementAfsaneh Amouzegar, Shannon Haig, Adriana M Kahn, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2019
Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 InhibitorsJack M Qian, James B Yu, Amit Mahajan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2026
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancerPaul Stockhammer, Talal El Zarif, Jacob L Schillo, et al.
The Lancet. Oncology|March 3, 2022
Yale Precision Medicine Tumor Board: reawakening the guardian of the genomeMichael J Grant, Karin E Finberg, Zenta Walther, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
American Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
Evaluation of quantitative modeling methods in whole-body, dynamic [<sup>11</sup>C]-erlotinib PETJoseph Ryan Petrulli, Mingqiang Zheng, Yiyun Huang, et al.
The Lancet. Oncology|September 20, 2020
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testingNavid Hafez, Zenta Walther, Joseph P Eder, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2016
Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary OligometastasesNataniel H Lester-Coll, Charles E Rutter, Trevor J Bledsoe, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Pageof 11

Showing results (21-30 of 105) with videos related to

Sort By:
Pageof 11
Radiology|September 19, 2018
Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database StudyJohannes Uhlig, Johannes M Ludwig, Sarah B Goldberg, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2024
Navigating the Complexities of Brain Metastases ManagementAfsaneh Amouzegar, Shannon Haig, Adriana M Kahn, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2019
Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 InhibitorsJack M Qian, James B Yu, Amit Mahajan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 3, 2026
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancerPaul Stockhammer, Talal El Zarif, Jacob L Schillo, et al.
The Lancet. Oncology|March 3, 2022
Yale Precision Medicine Tumor Board: reawakening the guardian of the genomeMichael J Grant, Karin E Finberg, Zenta Walther, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
American Journal of Nuclear Medicine and Molecular Imaging|June 3, 2021
Evaluation of quantitative modeling methods in whole-body, dynamic [<sup>11</sup>C]-erlotinib PETJoseph Ryan Petrulli, Mingqiang Zheng, Yiyun Huang, et al.
The Lancet. Oncology|September 20, 2020
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testingNavid Hafez, Zenta Walther, Joseph P Eder, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2016
Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary OligometastasesNataniel H Lester-Coll, Charles E Rutter, Trevor J Bledsoe, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Pageof 11